-
公开(公告)号:US11419923B2
公开(公告)日:2022-08-23
申请号:US16843118
申请日:2020-04-08
申请人: In3Bio Ltd.
IPC分类号: A61K39/00 , C07K14/475 , C07K14/485 , C07K14/495 , C07K14/50
摘要: The present disclosure provides for a synthetic immunogenic protein for use as an immuno-modulatory agent to enhance mammalian immune reactions towards conjugated protein or peptide containing antigens that are otherwise poorly immunogenic, including but not limited to self-antigens. The chimeric immunogenic proteins of the present disclosure can be used in the treatment of many illnesses, including but not limited to cancers, infectious disease, autoimmune disease, allergies and any clinical indication involving or affected by the immune response of a mammalian host.
-
公开(公告)号:US20220160609A1
公开(公告)日:2022-05-26
申请号:US17599061
申请日:2017-06-01
发明人: Sun Kyo LEE , Seong Ran LEE , Han Bong RYU , Tae Hyun KIM
IPC分类号: A61K8/64 , A61Q19/08 , C07K14/485 , C12N15/70
摘要: A fusion protein according to an embodiment of the present disclosure includes a growth differentiation factor 11 and an epidermal growth factor with an enhanced anti-oxidation activity and an enhanced skin cell proliferation effect, A cosmetic composition according to an embodiment of the present disclosure includes the fusion protein as an effective component. The cosmetic composition can be advantageously used in future as a material of a functional cosmetic product.
-
公开(公告)号:US20220073637A1
公开(公告)日:2022-03-10
申请号:US17256553
申请日:2019-07-01
申请人: CITY OF HOPE
IPC分类号: C07K16/28 , C07K14/485 , C07K16/46
摘要: Provided herein are, inter alia, anti-CD6 antibody-growth factor complexes including an anti-CD6 antibody portion bound to a growth factor protein (e.g., EGF) through a linker, which may be cleavable by a protease (e.g., diabetic microenvironment specific protease). The compositions provided herein are, inter alia, useful for the treatment of autoimmune diseases (e.g., type I diabetes).
-
公开(公告)号:US11248037B2
公开(公告)日:2022-02-15
申请号:US16417969
申请日:2019-05-21
申请人: Zymeworks Inc.
IPC分类号: C07K14/765 , C07K16/28 , C07K14/76 , C07K16/00 , C07K14/485 , C07K14/605 , C07K16/40
摘要: Provided herein are multifunctional heteromultimer proteins. In specific embodiments is a heteromultimer comprising: at least two polypeptide constructs, each polypeptide construct comprising at least one cargo polypeptide attached to a transporter polypeptide, said transporter polypeptides derived from a monomeric native protein such that said monomeric constructs associate to form the heteromultimer and said transporter polypeptides associate to form a quasi-native structure of the monomeric native protein or analog thereof. These therapeutically novel molecules encompass heteromultimers comprising constructs that function as scaffolds for the conjugation or fusion of therapeutic molecular entities (cargo polypeptides) resulting in the creation of bispecific or multivalent molecular species. Provided herein is a method for creation of bispecific or multivalent molecular species.
-
公开(公告)号:US11191817B2
公开(公告)日:2021-12-07
申请号:US16858514
申请日:2020-04-24
发明人: Ronald B. Moss
IPC分类号: A61K39/00 , A61K38/46 , C12N7/00 , A61K38/16 , C07K14/52 , C07K14/54 , C07K14/705 , C07K14/81 , C07K14/485 , C12N9/24
摘要: The present disclosure provides compositions and methods for treating an infection by EV-D68. In particular, the present disclosure provides methods that entail administering agents having an anchoring domain that anchors the compound to the surface of a target cell, and a sialidase domain that can act extracellularly to inhibit infection of a target cell by EV-D68.
-
6.
公开(公告)号:US20210299278A1
公开(公告)日:2021-09-30
申请号:US17020522
申请日:2020-09-14
申请人: ModernaTX, Inc.
发明人: Stephane BANCEL , Tirtha CHAKRABORTY , Antonin DE FOUGEROLLES , Sayda M. ELBASHIR , Matthias JOHN , Atanu ROY , Susan WHORISKEY , Kristy M. WOOD , Paul HATALA , Jason P. SCHRUM , Kenechi EJEBE , Jeff Lynn ELLSWORTH , Justin GUILD
IPC分类号: A61K48/00 , C12N15/85 , C07K14/47 , C07K14/62 , A61K31/7115 , C12N9/88 , A61K9/127 , C12N15/11 , C07K14/705 , C07K14/505 , C07K14/535 , C12N9/64 , C12N9/10 , C12N9/00 , C12N9/42 , C12N15/87 , C12P13/04 , A61K38/45 , C07K14/005 , C12N9/16 , C12N9/24 , C12N15/52 , A61K38/17 , C07K14/435 , C12P21/00 , C07K14/485 , C07H21/02 , C07K14/475 , C07K14/495 , C07K14/525 , C07K14/54 , C07K14/56 , C07K14/61 , C07K14/745 , C07K16/28 , C07K16/40 , C12N9/02 , C12N9/12 , C12N9/68 , A61K47/54 , A61K9/14 , A61K9/51 , A61K38/18 , A61K38/19 , A61K38/21 , A61K38/48 , C07K14/515 , C07K16/00
摘要: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
-
公开(公告)号:US11078255B2
公开(公告)日:2021-08-03
申请号:US16550803
申请日:2019-08-26
申请人: SYMTHERA CANADA LTD.
发明人: Chai Ezerzer
IPC分类号: C07K14/71 , C07K14/47 , G01N33/74 , C07K14/485
摘要: Disclosed are binding agents that include (a) a calcium binding portion which includes an F-helix peptide and a calcium binding loop peptide derived from an EF-hand motif of a calcium binding protein, wherein the C-terminus of the F-helix peptide is covalently linked to the N-terminus of the calcium binding loop peptide by a peptide bond, and (b) a targeting peptide, wherein the N-terminus of the targeting peptide is covalently linked to the C-terminus of the calcium binding portion by a peptide bond. The binding agents can be used for diagnosis and treatment of various disorders.
-
公开(公告)号:US20210188931A1
公开(公告)日:2021-06-24
申请号:US16757823
申请日:2018-10-23
申请人: PROGEN CO., LTD.
发明人: Zungyoon YANG , Eun Joo NAM
IPC分类号: C07K14/485 , C12P21/02 , A61K8/64 , A61Q19/00
摘要: A modified EGF protein, a production method therefor, and a use thereof are disclosed. The modified EGF protein allows an effective delivery of EGF into the cell and exhibits an enhanced half-life span. A method for producing the modified EGF protein includes culturing conditions where host cell growth phase and protein expression phase employ different temperature conditions. A use of the modified EGF protein is also disclosed.
-
公开(公告)号:US11028139B2
公开(公告)日:2021-06-08
申请号:US15994323
申请日:2018-05-31
申请人: NEXEL CO., LTD.
发明人: Choong Seong Han , Dong Hun Woo , Gun Sik Cho , Jeong Seong Kim , Geun Ho An , Hye Ryeon Jeon
IPC分类号: A61K38/17 , C07K14/47 , C07K14/485 , A61P1/16 , A61K38/00
摘要: The present invention relates to a recombinant protein for preventing or treating tissue fibrosis, which is based on milk fat globule-EGF factor 8 (MFG-E8) protein and comprises the amino acid sequence of SEQ ID NO: 1, and to a composition for preventing or treating tissue fibrosis, which comprises the recombinant protein. The level of the effect of preventing or treating tissue fibrosis by the recombinant protein of the present invention is significantly improved compared to that of conventional milk fat globule-EGF factor 8 (MFG-E8) protein, so that the level of tissue fibrosis can be restored to a level very close to that in normal tissue by the prevention and treatment of tissue fibrosis.
-
公开(公告)号:US20210128687A1
公开(公告)日:2021-05-06
申请号:US17126351
申请日:2020-12-18
申请人: Mind-NRG Sàrl
发明人: André SCHRATTENHOLZ
IPC分类号: A61K38/18 , A61K31/5513 , C07K14/475 , A61K45/06 , C07K14/485
摘要: The present invention refers to soluble Neuregulin-1 isoforms representing Posttranslational Neuregulin-1 modifications as medication in cognition-related neurological disorders, in particular schizophrenia, Alzheimer's and Parkinson's diseases.
-
-
-
-
-
-
-
-
-